ClinicalTrials.gg
Sign In
RecruitingNCT07341490TadaaUpdated Mar 17, 2026

CT-Angiography Versus Angiogram as Ancillary Tests in the Determination of Death by Neurologic Criteria

An observational study in Infarction, Brain, sponsored by Region Stockholm. Recruiting at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-17.

Sponsored by Region Stockholm · Observational

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

Diagnostic performance of a novel protocol for computed tomography-angiography, as ancillary test in the determination of complete cerebral infarction, in comparison to four vessel angiography.

02

Conditions studied

  • Infarction, Brain

Keywords

  • Cerebral infarction
  • Cerebral angiography
  • CT angiography
  • Brain Death
  • Diagnostic performance
  • Brain infarct
03

In context

Brain Infarction

93 studies on the registry are indexed under Brain Infarction; 19 are open to participants now.

This study's planned enrollment of 50 is below the median of 477 across 23 observational studies indexed under Brain Infarction.

Browse Brain Infarction studies →

Lead sponsor

Region Stockholm is the lead sponsor of 121 studies on the registry; 69 are open to participants now.

Browse Region Stockholm studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients receiving critical care

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years or older
  • Ongoing critical care due to severe acute brain injury
  • Four vessel angiography necessary for the determination of complete cerebral infarction, according to Swedish legislation

Exclusion criteria

Exclusion Criteria:

  • Treatment with extracorporeal membrane oxygenation (ECMO)
  • Radiologic examination by computed tomography deemed too challenging due to respiratory or circulatory instability, as determined by responsible clinician
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Suspected Complete Cerebral Infarction

    Patients with severe acute brain injury, in whom complete cerebral infarction has been declared by direct neurological criteria, but ancillary testing is warranted due to specific circumstances.

06

What researchers measure

Primary outcomes

  1. Diagnostic performance similar between computed tomography-angiography and four vessel angiography

    Sensitivity, specificity, positive predictive value, negative predictive value, inter- and intrarater variability.

    Time frame: Periprocedural

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Observational, exploratory

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2026 (actual). Primary completion is estimated for Dec 2028, 35 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2025
First posted
Jan 14, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Mar 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341490
Lead sponsor
Region Stockholm
Collaborators
Karolinska Institutet
Responsible party
Peter Rudberg (M.D. Ph.D., Karolinska Institutet) — Principal investigator
First posted
Jan 14, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 17, 2026

Study contacts

Peter C Rudberg, M.D. Ph.D.
Contact
peter.rudberg@ki.se
+46-8-1237000 ext. 72341
Anja Rosén, M.D.
Contact
anja.rosen@ki.se
+46-8-12370000 ext. 94856

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Brain Infarction →

Other studies from this sponsor

Region Stockholm →

Start the discussion